Immunization Safety Review: Multiple Immunizations and Immune Dysfunction (2002)
Chapter: Appendix A Chronology of Important Events Regarding Vaccine Safety
Appendix A
Chronology of Important Events Regarding Vaccine Safety
|
Year |
Vaccine Licensure |
Legislation and/or Policy Statements |
IOM Reports on Vaccine Safety |
|
1955 |
Inactivated poliomyelitis vaccine (IPV) available |
|
|
|
1963 |
Oral poliomyelitis vaccine (OPV) available, replaces IPV |
||
|
|
Measles vaccine available |
||
|
1967 |
Mumps vaccine available |
||
|
1969 |
Rubella vaccine available |
||
|
1971 |
Measles-Mumps-Rubella (MMR) vaccine available |
||
|
1977 |
|
Mumps vaccination recommended |
Evaluation of Poliomyelitis Vaccines |
|
1979 |
Current formulation of Rubella vaccine available, replaces earlier versions |
|
|
|
1982 |
Plasma-derived hepatitis B vaccine available |
||
|
Year |
Vaccine Licensure |
Legislation and/or Policy Statements |
IOM Reports on Vaccine Safety |
|
1985 |
Hib vaccine licensed for children >15 months |
|
|
|
1986 |
|
Congress passes Public Law 99–660, the National Childhood Vaccine Injury Act (introduced in 1984) calls for: • est. of NVPO • est. of NVAC • est. of VICP • est. of ACCV IOM review of 1) pertussis and rubella, 2) routine child vaccines |
|
|
1988 |
|
Evaluation of Poliomyelitis Vaccine Policy Options |
|
|
1990 |
2 Hib conjugate vaccines licensed for use beginning at 2 months |
|
|
|
1991 |
Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in ACELIMUNE |
Hepatitis B recommended by ACIP for addition to childhood immunization schedule ACIP recommends Hib be added to childhood immunization schedule |
Adverse Effects of Pertussis and Rubella Vaccines |
|
1992 |
Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in Tripedia |
Hepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons with multiple sex partners) |
|
|
1993 |
Combined DTP and Hib vaccine (Tetramune) licensed |
|
|
|
1994 |
|
Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality DPT and Chronic Nervous System Dysfunction: A New Analysis |
|
|
Year |
Vaccine Licensure |
Legislation and/or Policy Statements |
IOM Reports on Vaccine Safety |
|
1995 |
Varicella virus vaccine available (Varivax) |
|
|
|
1996 |
DTaP vaccine (Tripedia and ACEL-IMUNE licensed for complete 5-dose series |
ACIP recommends using IPV for the first 2 polio vaccinations, followed by OPV for remaining doses. Intended to be a transitional schedule for 3–5 years until an all -IPV series is available ACIP recommends children 12months—12 years receive Varicella vaccin |
Options for Poliomyelitis Vaccinations in the United States: Workshop Summary |
|
1997 |
Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part series |
ACIP recommends DTaP in place of DTP |
Vaccine Safety Forum: Summary of Two Workshops Risk Communication and Vaccination: Workshop Summary |
|
1998 |
Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part series |
ACIP updates MMR recommendation, encouraging use of the combined MMR vaccine 1999 ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry ACIP recommends an all-IPV schedule begin January 2000 to prevent cases of vaccine-associated paralytic polio AAP and PHS recommend removal of thimerosal from vaccines Also recommended postponement of hepatitis B vaccine from birth to 2–6 months for infants of hepatitis B surface antigen-negative mothers |
|
|
|
Additional supply of thimerosal-free hepatitis B vaccine made available |
MMWR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose |
|
|
Year |
Vaccine Licensure |
Legislation and/or Policy Statements |
IOM Reports on Vaccine Safety |
|
2000 |
Pneumococcal vaccine for infants and young children licensed (Prevnar) |
ACIP recommends pneumococcal vaccination for all children 2–23 months, and at-risk children 24–59 months (e.g., immunocompromised) |
|
|
2001 |
|
October: ACIP drafts statement expressing a preference for use of thimerosal-free DtaP, Hib, and Hep B vaccines by March 2002 |
Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders |
